Sanofi Forges $740M Partnership with Belharra to Pioneer Small Molecule Treatments for Immunological Diseases

San Mateo, CA and San Diego, June 18, 2024 (Globe Newswire) -- Belharra Therapeutics and Sanofi have partnered to discover novel small molecule therapies for immunological diseases using Belharra’s chemoproteomics platform. Sanofi will manage the preclinical, clinical, and commercial stages, with Belharra potentially earning nearly $740 million in milestone payments and royalties. This strategic collaboration aims to leverage Belharra’s cutting-edge technology to advance Sanofi’s pipeline of immunology treatments.

Read full article here.